# Isabelle Ray‐Coquard

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/isabelle-ray-coquard/

## Facts

| Field | Value |
| --- | --- |
| Citations | 44,603 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 102 |
| i10-index | 354 |
| Last Known Institution | Université Claude Bernard Lyon 1 |
| OpenAlex ID | https://openalex.org/A5073713547 |
| ORCID iD | https://orcid.org/0000-0003-2472-8306 |
| Works | 1,061 |

## Researcher papers

Showing 12 of 13.

- [Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer](https://scholariq.org/papers/olaparib-plus-bevacizumab-as-first-line-maintenance-in-ovarian-cancer/)
- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial](https://scholariq.org/papers/bevacizumab-combined-with-chemotherapy-for-platinum-resistant-recurrent-ovarian/)
- [Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/rucaparib-in-relapsed-platinum-sensitive-high-grade-ovarian-carcinoma-ariel2/)
- [ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease](https://scholariq.org/papers/esmo-esgo-consensus-conference-recommendations-on-ovarian-cancer-pathology-and/)
- [<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma](https://scholariq.org/papers/i-brca-i-reversion-mutations-in-circulating-tumor-dna-predict-primary-and/)
- [The forefront of ovarian cancer therapy: update on PARP inhibitors](https://scholariq.org/papers/the-forefront-of-ovarian-cancer-therapy-update-on-parp-inhibitors/)
- [ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease](https://scholariq.org/papers/esgo-esmo-esp-consensus-conference-recommendations-on-ovarian-cancer-pathology/)
- [Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2](https://scholariq.org/papers/antitumor-activity-and-safety-of-the-parp-inhibitor-rucaparib-in-patients-with/)
- [Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase](https://scholariq.org/papers/operability-and-chemotherapy-responsiveness-in-advanced-low-grade-serous-ovarian/)
- [Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)](https://scholariq.org/papers/molecular-and-clinical-determinants-of-response-and-resistance-to-rucaparib-for/)
- [European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer](https://scholariq.org/papers/european-experts-consensus-brca-homologous-recombination-deficiency-testing-in/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Sarcoma Diagnosis and Treatment](https://scholariq.org/topics/sarcoma-diagnosis-and-treatment/)
- [Uterine Myomas and Treatments](https://scholariq.org/topics/uterine-myomas-and-treatments-2/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)

## Researcher university

- [Lyon 1 Université](https://scholariq.org/institutions/lyon-1-universite/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.